| Nome |
# |
|
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2, file dd9e0c64-a5a1-1e9c-e053-3a05fe0a45ef
|
194
|
|
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis, file dd9e0c68-0cac-1e9c-e053-3a05fe0a45ef
|
163
|
|
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport, file 434e308b-d925-4861-9964-f93e42abf870
|
116
|
|
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease., file dd9e0c65-ad37-1e9c-e053-3a05fe0a45ef
|
108
|
|
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis, file dd9e0c6a-7e23-1e9c-e053-3a05fe0a45ef
|
90
|
|
Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response, file dd9e0c67-cee2-1e9c-e053-3a05fe0a45ef
|
82
|
|
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study, file dd9e0c69-9a24-1e9c-e053-3a05fe0a45ef
|
78
|
|
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis, file dd9e0c67-c20d-1e9c-e053-3a05fe0a45ef
|
77
|
|
The role of sexual dysfunction and attachment style in migraine related quality of life, file dd9e0c67-3125-1e9c-e053-3a05fe0a45ef
|
69
|
|
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients, file dd9e0c68-05d3-1e9c-e053-3a05fe0a45ef
|
66
|
|
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis, file dd9e0c67-f68d-1e9c-e053-3a05fe0a45ef
|
63
|
|
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis, file dd9e0c67-e66e-1e9c-e053-3a05fe0a45ef
|
61
|
|
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis, file dd9e0c68-1de9-1e9c-e053-3a05fe0a45ef
|
61
|
|
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection, file dd9e0c63-595c-1e9c-e053-3a05fe0a45ef
|
59
|
|
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice, file dd9e0c65-9cfa-1e9c-e053-3a05fe0a45ef
|
58
|
|
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies, file dd9e0c66-1496-1e9c-e053-3a05fe0a45ef
|
58
|
|
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort, file dd9e0c67-79a1-1e9c-e053-3a05fe0a45ef
|
58
|
|
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis, file dd9e0c67-ba00-1e9c-e053-3a05fe0a45ef
|
58
|
|
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient, file dd9e0c65-a016-1e9c-e053-3a05fe0a45ef
|
56
|
|
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study), file dd9e0c68-0474-1e9c-e053-3a05fe0a45ef
|
56
|
|
Development and validation of the ID-EC - The ITALIAN version of the identify chronic migraine, file dd9e0c68-1fa3-1e9c-e053-3a05fe0a45ef
|
56
|
|
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview, file dd9e0c68-0a1c-1e9c-e053-3a05fe0a45ef
|
55
|
|
Managing the transition (ManTra): A resource for persons with secondary progressive multiple sclerosis and their health professionals: Protocol for a mixed-methods study in Italy, file dd9e0c67-c8af-1e9c-e053-3a05fe0a45ef
|
54
|
|
A systematic review of the incidence and prevalence of cancer in multiple sclerosis, file dd9e0c68-0a12-1e9c-e053-3a05fe0a45ef
|
54
|
|
Complexity of MS management in the current treatment era, file dd9e0c67-b9f5-1e9c-e053-3a05fe0a45ef
|
53
|
|
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort, file dd9e0c64-9c73-1e9c-e053-3a05fe0a45ef
|
52
|
|
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy, file dd9e0c67-b444-1e9c-e053-3a05fe0a45ef
|
51
|
|
Comparative efficacy of switching to natalizumab in active multiple sclerosis, file dd9e0c68-08f9-1e9c-e053-3a05fe0a45ef
|
51
|
|
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry, file dd9e0c68-1032-1e9c-e053-3a05fe0a45ef
|
51
|
|
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis, file dd9e0c68-170a-1e9c-e053-3a05fe0a45ef
|
51
|
|
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?, file dd9e0c68-2389-1e9c-e053-3a05fe0a45ef
|
51
|
|
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis, file dd9e0c68-194c-1e9c-e053-3a05fe0a45ef
|
50
|
|
The challenge of comorbidity in clinical trials for multiple sclerosis, file dd9e0c67-c763-1e9c-e053-3a05fe0a45ef
|
49
|
|
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity, file dd9e0c67-d213-1e9c-e053-3a05fe0a45ef
|
49
|
|
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms, file dd9e0c67-fbfe-1e9c-e053-3a05fe0a45ef
|
49
|
|
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study, file dd9e0c67-ff88-1e9c-e053-3a05fe0a45ef
|
48
|
|
Recommendations for observational studies of comorbidity in multiple sclerosis, file dd9e0c68-08ad-1e9c-e053-3a05fe0a45ef
|
48
|
|
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting, file dd9e0c68-115b-1e9c-e053-3a05fe0a45ef
|
48
|
|
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis, file dd9e0c6a-615d-1e9c-e053-3a05fe0a45ef
|
48
|
|
Predictors of long-term disability accrual in relapse-onset multiple sclerosis, file dd9e0c67-eb67-1e9c-e053-3a05fe0a45ef
|
47
|
|
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations, file dd9e0c67-ed44-1e9c-e053-3a05fe0a45ef
|
47
|
|
Predictors of disability worsening in clinically isolated syndrome, file dd9e0c68-06fc-1e9c-e053-3a05fe0a45ef
|
47
|
|
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS, file dd9e0c67-e10f-1e9c-e053-3a05fe0a45ef
|
46
|
|
Defining reliable disability outcomes in multiple sclerosis, file dd9e0c67-e4a4-1e9c-e053-3a05fe0a45ef
|
43
|
|
The Italian multiple sclerosis register, file dd9e0c67-d3c0-1e9c-e053-3a05fe0a45ef
|
42
|
|
Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS, file dd9e0c68-11f8-1e9c-e053-3a05fe0a45ef
|
42
|
|
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP), file dd9e0c6a-6225-1e9c-e053-3a05fe0a45ef
|
40
|
|
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study, file dd9e0c68-115f-1e9c-e053-3a05fe0a45ef
|
36
|
|
Prognostic indicators in pediatric clinically isolated syndrome, file dd9e0c69-f007-1e9c-e053-3a05fe0a45ef
|
32
|
|
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis, file dd9e0c67-d3c2-1e9c-e053-3a05fe0a45ef
|
30
|
|
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis, file dd9e0c68-f53e-1e9c-e053-3a05fe0a45ef
|
30
|
|
Risk knowledge in relapsing multiple sclerosis (RIKNO 1.0) - Development of an outcome instrument for educational interventions, file dd9e0c68-103c-1e9c-e053-3a05fe0a45ef
|
28
|
|
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding, file dd9e0c6b-e55a-1e9c-e053-3a05fe0a45ef
|
23
|
|
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport, file dd9e0c68-0479-1e9c-e053-3a05fe0a45ef
|
15
|
|
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies, file dd9e0c6a-4242-1e9c-e053-3a05fe0a45ef
|
11
|
|
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy, file dd9e0c6a-b47a-1e9c-e053-3a05fe0a45ef
|
9
|
|
Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity, file dd9e0c63-adcd-1e9c-e053-3a05fe0a45ef
|
8
|
|
Durvalumab and multiple sclerosis: a causal link or simple unmasking?, file dd9e0c68-b33b-1e9c-e053-3a05fe0a45ef
|
6
|
|
Seasonal variation of relapse rate in multiple sclerosis is latitude dependent, file dd9e0c63-0e3a-1e9c-e053-3a05fe0a45ef
|
5
|
|
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis, file dd9e0c64-9445-1e9c-e053-3a05fe0a45ef
|
5
|
|
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks, file dd9e0c67-bad3-1e9c-e053-3a05fe0a45ef
|
5
|
|
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks, file dd9e0c68-02f0-1e9c-e053-3a05fe0a45ef
|
5
|
|
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study, file dd9e0c68-0470-1e9c-e053-3a05fe0a45ef
|
5
|
|
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS, file dd9e0c66-f79c-1e9c-e053-3a05fe0a45ef
|
4
|
|
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension, file dd9e0c67-bacd-1e9c-e053-3a05fe0a45ef
|
4
|
|
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis, file dd9e0c67-c681-1e9c-e053-3a05fe0a45ef
|
4
|
|
Natalizumab discontinuation and disease restart in pregnancy: A case series, file dd9e0c68-0e77-1e9c-e053-3a05fe0a45ef
|
4
|
|
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects, file dd9e0c66-89e6-1e9c-e053-3a05fe0a45ef
|
3
|
|
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels, file dd9e0c67-2e7b-1e9c-e053-3a05fe0a45ef
|
3
|
|
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, file dd9e0c67-d09e-1e9c-e053-3a05fe0a45ef
|
3
|
|
Treatment decisions in multiple sclerosis-insights from real-world observational studies, file dd9e0c67-f5c1-1e9c-e053-3a05fe0a45ef
|
3
|
|
Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica, file dd9e0c6a-54f1-1e9c-e053-3a05fe0a45ef
|
3
|
|
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics, file dd9e0c6a-9372-1e9c-e053-3a05fe0a45ef
|
3
|
|
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France, file dd9e0c6b-9e2d-1e9c-e053-3a05fe0a45ef
|
3
|
|
Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study, file 85370141-ef2e-43ac-8567-738771398754
|
2
|
|
DISABILITA' VISIVA NELLA NEUROPATIA OTTICA EREDITARIA DI LEBER. DALLA DIAGNOSI PRECOCE ALLA RIABILITAZIONE, file dd9e0c62-5de8-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c63-ba5c-1e9c-e053-3a05fe0a45ef
|
2
|
|
Sclerosi Multipla e Lavoro: dati preliminari, file dd9e0c66-e6e8-1e9c-e053-3a05fe0a45ef
|
2
|
|
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI, file dd9e0c67-3a30-1e9c-e053-3a05fe0a45ef
|
2
|
|
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome, file dd9e0c67-4a30-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c67-9274-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c67-cc1f-1e9c-e053-3a05fe0a45ef
|
2
|
|
Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis, file dd9e0c67-d507-1e9c-e053-3a05fe0a45ef
|
2
|
|
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study, file dd9e0c67-d5ec-1e9c-e053-3a05fe0a45ef
|
2
|
|
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta, file dd9e0c68-0ab4-1e9c-e053-3a05fe0a45ef
|
2
|
|
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study, file dd9e0c68-0cea-1e9c-e053-3a05fe0a45ef
|
2
|
|
Multiple sclerosis registries in Europe – An updated mapping survey, file dd9e0c68-0fa6-1e9c-e053-3a05fe0a45ef
|
2
|
|
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis, file dd9e0c68-11f2-1e9c-e053-3a05fe0a45ef
|
2
|
|
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment, file dd9e0c68-1fa9-1e9c-e053-3a05fe0a45ef
|
2
|
|
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis, file dd9e0c68-aa2b-1e9c-e053-3a05fe0a45ef
|
2
|
|
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide, file dd9e0c68-b32b-1e9c-e053-3a05fe0a45ef
|
2
|
|
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context, file dd9e0c6b-6762-1e9c-e053-3a05fe0a45ef
|
2
|
|
Disability assessment using Google Maps, file dd9e0c6b-8ba9-1e9c-e053-3a05fe0a45ef
|
2
|
|
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method, file dd9e0c6b-8bbb-1e9c-e053-3a05fe0a45ef
|
2
|
|
Risk of Getting COVID-19 in People With Multiple Sclerosis, file dd9e0c6b-c022-1e9c-e053-3a05fe0a45ef
|
2
|
|
Case report: LAMC3-associated cortical malformations: Case report of a novel stop-gain variant and literature review, file d7f0d883-1804-4705-bd32-6cb1f8256543
|
1
|
|
Serum and
CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis
optica, file dd9e0c63-13c9-1e9c-e053-3a05fe0a45ef
|
1
|
|
Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination., file dd9e0c63-b398-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c63-ba54-1e9c-e053-3a05fe0a45ef
|
1
|
|
Long term results of immunomodulatory treatment in children and adolescents with multiple
sclerosis: the Italian experience, file dd9e0c63-bb0a-1e9c-e053-3a05fe0a45ef
|
1
|
| Totale |
3.290 |